Document:

Exhibit 10.7

 

EXECUTION COPY

EXHIBIT F

 

FORTRESS RESTRICTIVE COVENANT AGREEMENT

 

THIS FORTRESS RESTRICTIVE
COVENANT AGREEMENT (as may be amended or modified from time to time, this “Agreement”) is made and entered
into as of November 12, 2018, by and between InvaGen Pharmaceuticals Inc., a New York corporation (“Buyer”),
and Fortress Biotech, Inc., a Delaware corporation (“Fortress”).

 

WHEREAS, Avenue
Therapeutics, Inc., a Delaware corporation (the “Company”), Madison Pharmaceuticals Inc., and Buyer have entered
into that certain Stock Purchase and Merger Agreement, dated as of the date hereof (the “SPMA”); and

 

WHEREAS, Fortress
is receiving a substantial economic benefit from the transactions contemplated by the SPMA, and Buyer would not have entered into
the SPMA without the execution and delivery by Fortress of this Agreement.

 

NOW THEREFORE,
in consideration of the mutual promises and covenants contained herein, and other good and valuable consideration, the receipt
and adequacy of which are hereby acknowledged, the parties agree as follows:

 

1.   
      Definitions. Capitalized terms used but not defined in this Agreement
shall have the respective meanings ascribed to them in the SPMA.

 

2.     
     Restrictive Covenants.

 

(a)          For a
period commencing on the date hereof and ending on the earlier of (i) (x) the termination of the SPMA in accordance with its terms
if at the time of such termination the First Stage Closing has not occurred or (y) the date that is five years after the termination
of the SPMA in accordance with its terms if at the time of such termination the First Stage Closing has occurred and (ii) five
years after the Second Stage Closing Date (such period, the “Term”), Fortress shall (1) not (and Fortress shall
cause its Affiliates, other than the Designated Affiliates, not to), on its own or through any other Person, engage or participate
in, or render services to (whether as owner, operator, member, stockholder, manager, consultant, strategic partner, employee or
otherwise) any Person engaged in, the business of hospital administered pain management anywhere in the world other than Canada,
Central America or South America, including licensing, acquiring or seeking to develop Intellectual Property relating in any manner
to hospital administered pain management, including by means of a collaboration agreement, partnership, joint venture, or other
investment, or through sponsorship, management, research or development arrangements and (2) be deemed to be in breach of this
Agreement if either of the Designated Affiliates, on its own or through any other Person, engages or participates in, or renders
services to (whether as owner, operator, member, stockholder, manager, consultant, strategic partner, employee or otherwise) any
Person engaged in, a business involving an FDA AP-rated 505(b)(2) NDA relating to the Product or an ANDA relating to the Product
anywhere in the world other than Canada, Central America or South America, including licensing, acquiring or seeking to develop
Intellectual Property relating in any manner to an FDA AP-rated 505(b)(2) NDA relating to the Product or an ANDA relating to the
Product, including by means of a collaboration agreement, partnership, joint venture, or other investment, or through sponsorship,
management, research or development arrangements. During the Term, Fortress shall not (and Fortress shall cause its Affiliates
not to), directly or indirectly, use or transfer to another Person, or facilitate the use or transfer by or to another Person,
of any Investigational New Drug, NDA, “regulatory documents”, “essential documents” or any amendments thereto,
any data or information contained in the files submitted to the FDA, or any other information or data, in each case, related to
the Product or improvements thereon.

 

     

     

    

 

(b)         During
the Term, Fortress shall not (and Fortress shall cause its Affiliates, other than the Designated Affiliates, not to) directly or
indirectly, (i) solicit for employment, recruit or hire, either as an employee or a consultant, any employee, consultant or independent
contractor of the Company (other than as described in Schedule 1 hereto), Buyer, Cipla Limited (“Cipla”)
or any of their respective Affiliates who was an employee, consultant or independent contractor of the Company, Buyer, Cipla or
any of their respective Affiliates as of the date of this Agreement or at any time thereafter and prior to the expiration of the
Term to become an employee or consultant of, or otherwise provide services to, Fortress or any of its Affiliates, (ii) interfere
or attempt to interfere with any transaction, agreement, prospective agreement, business opportunity or business relationship relating
to the Product in which the Company, Buyer, Cipla or any of their respective Affiliates is involved in as of the date of this Agreement
or at any time thereafter and prior to the expiration of the Term or (iii) otherwise engage or participate in any effort or act
to induce any Person to discontinue a relationship with the Company, Buyer or Cipla or any of their respective Affiliates. During
the Term, Fortress shall be deemed to be in breach of this Agreement if either of the Designated Affiliates directly or indirectly,
interferes or attempts to interfere with any transaction, agreement, prospective agreement, business opportunity or business relationship
relating to the Product in which the Company, Buyer, Cipla or any of their respective Affiliates is involved in as of the date
of this Agreement or at any time thereafter and prior to the expiration of the Term.

 

(c)          Fortress
shall (and Fortress shall cause its Affiliates and Representatives to) keep confidential and not disclose to any other Person or
use any information, technology, know-how, trade secrets, product formulas, industrial designs, franchises, inventions or other
industrial and intellectual property in Fortress’ possession or control regarding the Company or its businesses (unless and
to the extent compelled to disclose by judicial or administrative process or, in the opinion of its counsel, by other Legal Requirements).
The obligations of Fortress under this Section 2(c) shall not apply to information that (i) is obtained from public information,
(ii) is received from a third party after the date hereof not, to the actual knowledge of Fortress after reasonable investigation,
subject to any obligation of confidentiality with respect to such information, or (iii) is or becomes known to the public, other
than through a breach of this Agreement.

 

    	2

     

    

 

(d)          For
purposes of this Agreement, “Designated Affiliate” shall mean each of Mustang Bio, Inc., a Delaware corporation
(“Mustang”), and Checkpoint Therapeutics, Inc., a Delaware corporation (“Checkpoint”), only
if (i) none of Fortress or its Affiliates (other than Mustang or Checkpoint) or Representatives have, directly or indirectly, provided
guidance or encouragement to, or suggested, requested or directed to, take any action which would constitute a failure to comply
with this Agreement if taken by Fortress and (ii) any designee of Fortress or any of its Affiliates on the board of directors (or
similar governing body) of Mustang or Checkpoint, as applicable, shall have recused himself or herself from participating in discussions
or voting with respect to the action which, but for the exception for Designated Affiliates in Section 2, would constitute
a failure to comply with this Agreement.

 

(d)          Fortress
hereby acknowledges and agrees that the provisions of this Agreement shall supersede the provisions of Section 1.3.2 of
the MSA (as defined in the Waiver Agreement).

 

3.     
     Representations and Warranties. Fortress represents and warrants to Buyer as follows:

 

(a)         (i)
It is a corporation duly organized, validly existing and in good standing under the laws of Delaware, (ii) it is duly licensed
and qualified to conduct its business in each jurisdiction where the nature of the properties owned, leased or operated by it and
the business transacted by it requires such licensing or qualification, except where any such failures to be so qualified or licensed
have not had, or are not reasonably likely to have, a material adverse effect on the ability of Fortress to perform its obligations
under or to consummate the transactions contemplated by this Agreement, and (iii) it holds all necessary corporate power and authority
to own, license and operate its assets and properties, to conduct its business, to enter into this Agreement, to perform its obligations
hereunder and to consummate the transactions contemplated hereby.

 

(b)          The
execution and delivery of this Agreement by Fortress and the performance by Fortress of its obligations hereunder have been duly
authorized by all requisite action on the part of Fortress, and no other actions or proceedings on the part of Fortress are necessary
to authorize the execution and delivery of this Agreement.

 

(c)          This
Agreement has been duly executed and delivered by Fortress and constitutes the valid and binding agreement of Fortress, enforceable
against Fortress in accordance with its terms.

 

(c)          The
execution or delivery by Fortress of this Agreement or the performance by Fortress of its obligations under this Agreement will
not (i) result in any breach of any provision of Fortress’ certificate of incorporation or bylaws, as amended, (ii) result
in any breach of, require (with or without notice or lapse of time or both) any payment, consent or notice or constitute a default
(or give rise to any right of purchase, termination, amendment, acceleration or cancellation) under any Contract or order or judgment
to which Fortress is a party or by which it or its assets are bound, (iii) result in the creation of an Encumbrance, or (iv) violate
any applicable Legal Requirement, other than, in the case of clauses (ii) through (iv), such breaches, defaults or violations that
have not had, or are not reasonably likely to have, a material adverse effect on the ability of Fortress to perform its obligations
under or to consummate the transactions contemplated by this Agreement.

 

    	3

     

    

 

4.     
     Remedies. Buyer and Fortress acknowledge and agree that the remedies at law for any
breach by Fortress of any of the covenants or provisions of this Agreement are inadequate, and that Buyer shall be entitled
to an injunction, specific performance or other equitable relief against Fortress in the event of any breach, Fortress agrees
to reimburse Buyer any and all fees, costs and expenses (including reasonable attorneys’ fees) incurred for purposes of
enforcing this Agreement in the event such enforcement is either consented to by Fortress or ordered by a court of competent
jurisdiction. Without limiting the foregoing, in the event of a breach or threatened breach by Fortress of the terms of this
Agreement, Buyer shall be entitled, if it so elects, to: (a) have the provisions of this Agreement specifically enforced by
any court having equity jurisdiction or to enjoin Fortress from any further violation of this Agreement; (b) require Fortress
to account for and pay over to Buyer all compensation, profits, monies, accruals, increments or other benefits derived or
received by Fortress as the result of any transactions constituting a breach of this Agreement, and Fortress hereby agrees to
promptly account for and pay over such benefits to Buyer; and (c) institute legal proceedings to obtain other monetary
damages for any such breach. Without limiting the foregoing, Buyer shall be entitled to set-off any amount owed by
Fortress under this Agreement as a result of its breach hereof against any amount owed to Fortress or any of its Affiliates
under the SPMA or any Ancillary Agreement. Each of the rights and remedies enumerated above shall be independent of the
others, and shall be severally enforceable, and all of such rights and remedies shall be in addition to, and not in lieu of,
any other rights and remedies available to Buyer at law or in equity.

 

5.  
        Severability. In the event that any of the covenants or provisions
of Section 2 hereof may be determined to be invalid, illegal or unenforceable by a court of competent jurisdiction in
a final non-appealable judgment or order as a result of any time or scope (geographic or otherwise) limitations provided
therein, Buyer and Fortress expressly agree that such covenants and provisions shall be effective nevertheless for the
greatest period of time and within the greatest scope (geographic or otherwise) that would not render them invalid, illegal
or unenforceable, and in such event Fortress hereby consents that such provisions may be judicially modified accordingly in
any proceeding brought to enforce the provisions of Section 2 hereof. Any other covenant or provision of this
Agreement that may be determined to be invalid, illegal or unenforceable shall be ineffective only to the extent of such
invalidity, illegality or unenforceability without invalidating or rendering unenforceable any remaining provisions of this
Agreement.

 

6.    
      Tolling Period. The obligations contained in Section 2 hereof shall be
extended by any length of time during which Fortress is or was in breach of any such obligations.

 

    	4

     

    

 

7.    
      Acknowledgments. Fortress hereby acknowledges and agrees that (a) this
Agreement (including the time, scope (geographic or otherwise) or any other limitations provided in Section 2 hereof)
is reasonable and necessary for the protection of the immediate interests of Buyer, and that any violation of this Agreement
would cause substantial injury to Buyer and that Buyer would not have entered into the SPMA, this Agreement and the other
Ancillary Agreements without receiving the additional consideration offered by Fortress in binding itself to this Agreement;
(b) the scope of this Agreement, in terms of duration, geographic area, activities restricted and otherwise, is reasonable;
and (c) counsel for Fortress has reviewed this Agreement.

 

8.
          Miscellaneous.

 

		a.	Entire Agreement. This Agreement constitutes the
entire agreement between the parties hereto with respect to the subject matter of this Agreement and supersedes any and all prior
agreements, negotiations, correspondence, undertakings, understandings and communications of the parties hereto with respect to
the subject matter of this Agreement.

 

		b.	Transaction Costs. Except as otherwise provided
herein, the parties to this Agreement will pay their own costs and expenses (including legal, accounting and other fees) relating
to this Agreement.

 

		c.	Modifications. Any amendment or modification to
this Agreement, including this undertaking itself, shall only be valid if effected by an instrument or instruments in writing
and shall be effective against each of the parties hereto that has signed such instrument or instruments. The parties agree that
they jointly negotiated and prepared this Agreement and that this Agreement will not be construed against any party on the grounds
that such party prepared or drafted the same.

 

		d.	Notices.
                                         Notices will be deemed to have been received (a) upon
                                         receipt of a registered letter, (b) three Business Days following proper deposit with
                                         an internationally recognized express overnight delivery service, or (c) in the case
                                         of transmission by email, as of the date so transmitted (or if so transmitted after normal
                                         business hours at the place of the recipient, on the Business Day following such transmission):

 

If to Fortress:

 

Fortress Biotech, Inc.

2 Gansevoort Street, 9th Floor

New York, NY 10014

Attn: Dr. Lindsay Rosenwald, M.D.

Email: lrosenwald@fortressbiotech.com

 

With a copy (which shall not constitute
notice) to:

 

Fortress Biotech, Inc.

2 Gansevoort Street, 9th Floor

New York, NY 10014

Attn: Samuel W. Berry, Esq.

Email: sberry@fortressbiotech.com

 

    	5

     

    

 

If to Buyer:

 

InvaGen Pharmaceuticals Inc.

Site B, 7 Oser Ave.

Hauppauge, NY 11788

c/o

A.S. Kumar,
Esq.

Global General
Counsel

Cipla Ltd.

Cipla House,
Peninsula Business Park,

Ganapatrao
Kadam Marg, Lower Parel West,

Mumbai, Maharashtra
400013, India

Email: as.kumar@cipla.com
and cosecretary@cipla.com

 

With a copy (which shall not constitute
notice) to:

 

InvaGen Pharmaceuticals Inc.

Site B, 7 Oser Ave.

Hauppauge, NY 11788

c/o

Nishant Saxena

Global Chief Strategy Officer

Cipla Ltd.

Cipla House, Peninsula Business Park,

Ganapatrao Kadam Marg, Lower Parel West,

Mumbai, Maharashtra 400013, India

Email: nishant.saxena@cipla.com

 

With a copy (which shall not constitute
notice) to:

 

Hughes Hubbard & Reed LLP

One Battery Park Plaza

New York, NY 10004-1482

Attn: Kenneth A. Lefkowitz

Email: ken.lefkowitz@hugheshubbard.com

 

or to such other address as
may be hereafter communicated in writing by the parties in a notice given in accordance with this Section 8(d), which address
shall then apply to the respective notice provisions of the SPMA and all other Ancillary Agreements.

 

    	6

     

    

 

		e.	Public Announcements. Except as required by Legal
Requirements or by the requirements of any stock exchange on which the securities of a party hereto or any of its Affiliates are
listed, no party to this Agreement will make, or cause to be made, any press release or public announcement in respect of this
Agreement or the transactions contemplated hereby or otherwise communicate with any news media with respect to the foregoing without
prior notification to the other parties, and the parties to this Agreement will consult with each other and cooperate as to the
form, timing and contents of any such press release, public announcement or disclosure.

 

		f.	Severability.
                                         Each provision of this Agreement will be interpreted
                                         in such manner as to be effective and valid under applicable Legal Requirements, but
                                         if any provision of this Agreement is found to be unenforceable or invalid under applicable
                                         Legal Requirements, such provision will be ineffective only to the extent of such unenforceability
                                         or invalidity, and the parties will negotiate in good faith to modify this Agreement
                                         so that the unenforceable or invalid provision is replaced by such valid and enforceable
                                         provision which the parties consider, in good faith, to match as closely as possible
                                         the invalid or unenforceable provision and to achieve the same or a similar economic
                                         effect and to give effect to the parties’ original intent. The remaining provisions
                                         of this Agreement will continue to be binding and in full force and effect.

 

		g.	Assignment.
                                         No party hereto may assign, in whole or in part, or
                                         delegate all or any part of its rights, interests or obligations under this Agreement
                                         without the prior written consent of the other party. Any assignment or delegation made
                                         without such consent will be void. Notwithstanding the foregoing, Buyer shall be entitled
                                         to (a) assign its rights under this Agreement to any one of its Affiliates, and (b) assign
                                         any or all of its rights and obligations under this Agreement (in whole or in part) as
                                         collateral security in a financing transaction.

 

		h.	Governing
                                         Law. This Agreement
                                         and any claims or causes of action pursuant to it will be governed by and construed in
                                         accordance with the laws of the State of Delaware, without regard for its principles
                                         of conflict of laws.

 

		i.	Specific
                                         Performance. Each party
                                         acknowledges and agrees that the other party would be irreparably damaged if the provisions
                                         of this Agreement are not performed in accordance with their terms and that any breach
                                         of this Agreement and the non-consummation of the transactions contemplated hereby by
                                         either party could not be adequately compensated in all cases by monetary damages alone.
                                         Accordingly, in addition to any remedy to which such other party may be entitled under
                                         Section 8(j), provisional measures and injunctive relief necessary to protect
                                         the possibility of each party to seek specific performance from the other from the tribunal
                                         referred to in Section 8(j) can be sought from any court of competent jurisdiction.
                                         Each of the parties hereto (i) agrees that it shall not oppose the granting of any such
                                         relief and (ii) hereby irrevocably waives any requirement for the security or posting
                                         of any bond in connection with any such relief (it is understood that clause (i) of this
                                         sentence is not intended to, and shall not, preclude any party hereto from litigating
                                         on the merits the substantive claim to which such remedy relates).

 

    	7

     

    

 

		j.	Submission
                                         to Jurisdiction. Each
                                         of the parties hereto irrevocably agrees that any Proceeding with respect to this Agreement and
                                         the rights and obligations arising hereunder, or for recognition and enforcement of any
                                         judgment in respect of this Agreement and the rights and obligations arising
                                         hereunder brought by any other party hereto or its successors or assigns, shall be brought
                                         and determined exclusively in the Court of Chancery of the State of Delaware, or in the
                                         event (but only in the event) that such court does not have subject matter jurisdiction
                                         over such action or proceeding, in the federal courts sitting in the State of Delaware.
                                         Each of the parties hereto agrees that mailing of process or other papers in connection
                                         with any such action or proceeding in the manner provided in Section 8(d),
                                         or in such other manner as may be permitted by applicable Legal Requirements, will be
                                         valid and sufficient service thereof. Each of the parties hereto hereby irrevocably submits
                                         with regard to any such action or proceeding for itself and in respect of its property,
                                         generally and unconditionally, to the personal jurisdiction of the aforesaid courts and
                                         agrees that it will not bring any action relating to this Agreement or any
                                         of the transactions contemplated by this Agreement in any court or tribunal
                                         other than the aforesaid courts. Each of the parties hereto hereby irrevocably waives,
                                         and agrees not to assert, by way of motion, as a defense, counterclaim, or otherwise,
                                         in any action or proceeding with respect to this Agreement and the rights and
                                         obligations arising hereunder, or for recognition and enforcement of any judgment in
                                         respect of this Agreement and the rights and obligations arising hereunder:
                                         (a) any claim that it is not personally subject to the jurisdiction of the above named
                                         courts for any reason other than the failure to serve process in accordance with this Section
                                         8(j); (b) any claim that it or its property is exempt or immune from jurisdiction
                                         of any such court or from any legal process commenced in such courts (whether through
                                         service of notice, attachment prior to judgment, attachment in aid of execution of judgment,
                                         execution of judgment or otherwise); and (c) to the fullest extent permitted by the applicable
                                         Legal Requirements, any claim that (i) the suit, action or proceeding in such court is
                                         brought in an inconvenient forum, (ii) the venue of such suit, action or proceeding is
                                         improper, or (iii) this Agreement, or the subject matter hereof, may not be enforced
                                         in or by such courts.

 

    	8

     

    

 

		k.	Waiver
                                         of Jury Trial. EACH
                                         PARTY ACKNOWLEDGES AND AGREES THAT ANY CONTROVERSY WHICH MAY ARISE UNDER THIS AGREEMENT IS
                                         LIKELY TO INVOLVE COMPLICATED AND DIFFICULT ISSUES AND, THEREFORE, EACH SUCH PARTY IRREVOCABLY
                                         AND UNCONDITIONALLY WAIVES ANY RIGHT IT MAY HAVE TO A TRIAL BY JURY IN RESPECT OF ANY
                                         LEGAL ACTION ARISING OUT OF OR RELATING TO THIS AGREEMENT or
                                         the transactions contemplated hereby. EACH PARTY TO THIS AGREEMENT CERTIFIES
                                         AND ACKNOWLEDGES THAT: (A) NO REPRESENTATIVE OF ANY OTHER PARTY HAS REPRESENTED, EXPRESSLY
                                         OR OTHERWISE, THAT SUCH OTHER PARTY WOULD NOT SEEK TO ENFORCE THE FOREGOING WAIVER IN
                                         THE EVENT OF A LEGAL ACTION; (B) SUCH PARTY HAS CONSIDERED THE IMPLICATIONS OF THIS WAIVER;
                                         (C) SUCH PARTY MAKES THIS WAIVER VOLUNTARILY; AND (D) SUCH PARTY HAS BEEN INDUCED TO
                                         ENTER INTO THIS AGREEMENT BY, AMONG OTHER THINGS, THE MUTUAL WAIVERS AND CERTIFICATIONS
                                         IN THIS SECTION 8(k).

 

		l.	Waiver. Any term or condition of this Agreement
may be waived at any time by the party that is entitled to the benefit thereof, but no such waiver shall be effective unless set
forth in a written instrument duly executed by or on behalf of the party waiving such term or condition, and no waiver by any
party of any default, misrepresentation, or breach of warranty or covenant hereunder, shall be deemed to extend to any prior or
subsequent default, misrepresentation, or breach of warranty, covenant or agreement hereunder or affect in any way any rights
arising by virtue of any such prior or subsequent occurrence. No failure or delay of any party in exercising any right or remedy
hereunder shall operate as a waiver thereof, and no waiver by any party of any term or condition of this Agreement, in any one
or more instances, shall be deemed to be or construed as a waiver of the same or any other term or condition of this Agreement
on any future occasion.

 

		m.	Counterparts;
                                         Facsimile Signature. This
                                         Agreement may be executed in one (1) or more counterparts, by original or facsimile (or
                                         other such electronically transmitted) signature, each of which will be deemed an original,
                                         but all of which will constitute one and the same instrument. Any party executing this
                                         Agreement by facsimile (or other such electronically transmitted) signature shall, upon
                                         request from another party hereto, promptly deliver to the requesting party an original
                                         counterpart of such signature.

 

		n.	Rights
                                         Cumulative. All rights
                                         and remedies of each of the parties under this Agreement will be cumulative, and the
                                         exercise of one or more rights or remedies will not preclude the exercise of any other
                                         right or remedy available under this Agreement or applicable Legal Requirements.

 

    	9

     

    

 

		o.	Interpretation.
                                         (a) The words “hereof”,
                                         “herein”, and “hereunder” and words of similar import, when used
                                         in this Agreement, shall refer to this Agreement as a whole and not to any particular
                                         provision of this Agreement; (b) the words “date hereof,” when used
                                         in this Agreement, shall refer to the date set forth in the Preamble; (c) the terms
                                         defined in the singular have a comparable meaning when used in the plural, and vice versa;
                                         (d) the terms defined in the present tense have a comparable meaning when used in
                                         the past tense, and vice versa; (e) any references herein to a specific Section
                                         or Article shall refer, respectively, to Sections or Articles of this Agreement; (f) wherever
                                         the word “include”, “includes”, or “including” is
                                         used in this Agreement, it shall be deemed to be followed by the words “without
                                         limitation”; (g) references herein to any gender includes each other gender;
                                         (h) the word “or” shall not be exclusive; (i) the headings herein
                                         are for convenience of reference only, do not constitute part of this Agreement and shall
                                         not be deemed to limit or otherwise affect any of the provisions hereof; (j) any references
                                         herein to any Governmental Authority shall be deemed to also be a reference to any successor
                                         Governmental Authority thereto; and (k) the parties hereto have participated jointly
                                         in the negotiation and drafting of this Agreement and, in the event that an ambiguity
                                         or question of intent or interpretation arises, this Agreement shall be construed as
                                         jointly drafted by the parties hereto and no presumption or burden of proof shall arise
                                         favoring or disfavoring any party by virtue of the authorship of any provision of this
                                         Agreement.

 

		p.	Survival.
                                         This Section 8 shall survive any termination
                                         of this Agreement.

 

[SIGNATURE PAGE TO FOLLOW]

 

    	10

     

    

 

IN WITNESS WHEREOF, the parties hereto
have executed this Agreement as of the date first set forth above.

 

	Fortress Biotech, Inc.	 
	 	 	 
	By:	/s/  Lindsay A. Rosenwald	 
	Name:   	Lindsay A. Rosenwald	 
	Title:	President and CEO	 
	 	 	 
	InvaGen Pharmaceuticals Inc.	 
	 	 	 
	By:	/s/ Deepak Agarwal	 
	Name:   	Deepak Agarwal	 
	Title:	CFO	 

 

[Signature Page to Fortress Restrictive
Covenant Agreement]

 

     

     

    

 

Schedule 1

 

Robert Criscola – may leave the Company and transition
to an Affiliate of Fortress after the filing of the NDA by the Company.

 

Amy Wheeler – may leave the Company and transition to
an Affiliate of Fortress after the Company completes its abdominoplasty study.

 

[Signature Page to Fortress Restrictive
Covenant Agreement]Exhibit 10.8

 

EXECUTION
COPY

Exhibit
G

 

Indemnification
AGREEMENT

 

THIS Indemnification
AGREEMENT (as amended or modified from time to time, this “Agreement”) is made and entered into as
of November 12, 2018, by and among InvaGen Pharmaceuticals Inc., a New York Corporation (“Buyer”), and Fortress
Biotech, Inc., a Delaware corporation (“Fortress”).

 

RECITALS

 

WHEREAS, Buyer,
Madison Pharmaceuticals Inc., a Delaware corporation and wholly-owned Subsidiary of Buyer, and Avenue Therapeutics, Inc., a Delaware
corporation (the “Company”), have entered into that certain Stock Purchase and Merger Agreement, dated as of
the date of this Agreement (the “SPMA”); and

 

WHEREAS, Fortress
is receiving a substantial economic benefit from the transactions contemplated by the SPMA, and Buyer would not have entered into
the SPMA without the execution and delivery by Fortress of this Agreement.

 

NOW, THEREFORE,
in consideration of the foregoing and the respective representations and warranties, covenants and agreements set forth in this
Agreement, and other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, effective as
of the First Stage Closing (as defined in the SPMA) (the “Effective Date”), the parties hereto agree as follows:

 

		1.	Definitions.

 

Capitalized terms used
but not defined in this Agreement shall have the respective meanings ascribed to them in the SPMA.   

 

		2.	Indemnification.

 

(a)          Subject
to the other provisions of this Section 2, from the First Stage Closing until the Second Stage Closing (it being agreed
that any claim with respect to which Fortress has been given an Indemnification Notice at or prior to the Second Stage Closing
shall survive the Second Stage Closing or the termination of the SPMA pursuant to Section 10.5 thereof), Fortress agrees
to indemnify and hold harmless the Buyer Indemnified Parties from and against all Losses asserted (or to be asserted as of the
Second Stage Closing giving effect to the Second Stage Closing) against, imposed (or to be imposed as of the Second Stage Closing
giving effect to the Second Stage Closing) upon or sustained (to be sustained as of the Second Stage Closing giving effect to the
Second Stage Closing) or incurred (to be incurred as of the Second Stage Closing giving effect to the Second Stage Closing) as
a result of, arising out of or in connection with any breach or inaccuracy as of (i) the Signing Date, (ii) the First Stage Closing
Date as if made at and as of such time (except to the extent expressly made as of an earlier date, in which case as of such date)
and (iii) the Second Stage Closing Date as if made at and as of such time (except to the extent expressly made as of an earlier
date, in which case as of such date), in each case, of any representation or warranty of the Company contained in the SPMA or any
Ancillary Agreement, provided, that, in each case, for purposes of determining if there is any such breach or inaccuracy
and for purposes of calculating any Losses arising from such breach or inaccuracy, such representations and warranties shall be
read as if they were not qualified by any concept of “material,” “materiality” or “Material Adverse
Effect” or a similar qualification; provided that, such materiality read out shall not apply to the representations
contained in Section 5.4 and Section 5.10 of the SPMA and the defined term “Material Contract”, and provided further
that changes in the share price of the Common Shares shall not alone constitute a “Loss” for purposes of this Section
2).

 

    	 

     

    

 

(b)          Notwithstanding
anything in this Agreement to the contrary:

 

(i)           except
in the case of fraud or intentional misrepresentation, Fortress shall not be liable for any claim for indemnification pursuant
to Section 2(a) (other than with respect to any breach or inaccuracy of any Fundamental Representation) unless and until
the aggregate amount of indemnifiable Losses which may be recovered from Fortress equals or exceeds $150,000, in which case Fortress
shall be liable for the full amount of such Losses from the first dollar thereof;

 

(ii)          except
in the case of fraud or intentional misrepresentation, the maximum liability of Fortress pursuant to Section 2(a) (other
than with respect to any breach or inaccuracy of any Fundamental Representation) shall in no event exceed $7,000,000;

 

(iii)         except
in the case of fraud or intentional misrepresentation, the maximum liability of Fortress pursuant to Section 2(a) solely
with respect to any breach or inaccuracy of any Fundamental Representation shall in no event exceed $35,000,000; and

 

(iv)         except
in the case of fraud or intentional misrepresentation, in no event shall the maximum liability of Fortress pursuant to Section
2(a) exceed $35,000,000 in the aggregate.

 

(c)          Notwithstanding
anything in this Agreement to the contrary, in no event shall Losses of any Person include any punitive damages, except to the
extent payable to a third party. No investigation by any Person, or information provided, made available or delivered to any Person,
or any knowledge that any Person may have shall affect any representations or warranties or rights contained in this Agreement
or any Ancillary Agreement. Notwithstanding anything to the contrary, no Buyer Indemnified Party shall have any obligation to pursue
the Company for any Losses relating to any breach or inaccuracy of any representation or warranty of the Company contained in the
SPMA or in any Ancillary Agreement, and in no event shall Fortress or any of its Affiliates make any claim, including any claims
for contribution, against the Company, Buyer or their respective Affiliates with respect to any such breaches or inaccuracies or
with respect to any indemnification amounts paid or payable hereunder, the SPMA or any other Ancillary Agreement.

 

    	2

     

    

 

(d)          Fortress
and Buyer agree to treat all indemnification payments made under this Agreement as an adjustment to the Stock Purchase Price for
Tax purposes and shall be treated as such by Fortress and Buyer on their Tax Returns to the greatest extent permitted by Legal
Requirement.

 

(e)          From
the First Stage Closing until the Second Stage Closing, the indemnities provided for in this Section 2 are the sole and
exclusive monetary remedies of the Buyer Indemnified Parties against Fortress for any breach of or inaccuracy in any representations
or warranty of the Company set forth in the SPMA; it being understood that the foregoing limitations shall not apply in respect
of a claim of fraud or intentional misrepresentation. To the extent that Buyer has obtained the insurance coverage referred to
in Section 11 of the SPMA (the “R&WI”), Buyer shall first use reasonable best efforts to pursue any claims
that it could otherwise have brought against Fortress under this Section 2 against the insurer providing the R&WI to
the extent such claims are covered by the R&WI, it being agreed that Buyer shall not be limited to exercise its rights under
this Section 2 to the extent that (i) there is no R&WI or (ii) the R&WI does not cover Losses indemnifiable under
this Section 2 (including due to fraud or intentional misrepresentation), it being further agreed that nothing herein shall
preclude any Buyer Indemnified Party from (A) delivering an Indemnification Notice to Fortress (even though Buyer is pursuing the
insurer providing the R&WI), (B) pursuing Fortress hereunder if Buyer does not reach an agreement with the insurer providing
the R&WI within 30 days of making the claim to such insurer or (C) pursuing Fortress hereunder (without first pursuing the
insurer providing the R&WI) within 90 days prior to the Second Stage Closing.

 

(f)           Subject
to the other provisions of this Section 2, whenever any claim shall arise for indemnification under this Section 2,
the Buyer Indemnified Parties, shall notify Fortress in writing (the “Indemnification Notice”) within 30 days
of becoming aware of the claim, which writing shall include the facts reasonably available to the Buyer Indemnified Parties constituting
the basis for such claim, the specific section of the SPMA or Ancillary Agreement upon which the claim is based and an estimate,
if reasonable practicable, of the amount of Losses asserted (or to be asserted as of the Second Stage Closing giving effect to
the Second Stage Closing) against, imposed (or to be imposed as of the Second Stage Closing giving effect to the Second Stage Closing)
upon or sustained (to be sustained as of the Second Stage Closing giving effect to the Second Stage Closing) or incurred (to be
incurred as of the Second Stage Closing giving effect to the Second Stage Closing) by the Buyer Indemnified Party; provided,
however, that the failure of the Buyer Indemnified Party to provide such notice shall not affect the indemnification obligations
of Fortress except to the extent that Fortress is actually materially prejudiced as a result of such failure; provided, further,
that, without limiting the provisions of this Agreement, the Buyer Indemnified Parties shall have the right to deliver such Indemnification
Notice after the consummation of the First Stage Closing and prior to, or concurrently with, the consummation of the Second Stage
Closing with respect to any representation or warranty of the Company contained in the SPMA or any Ancillary Agreement that Buyer
in good faith expects will be breached or inaccurate as of the Second Stage Closing Date as if made at and as of such time (except
to the extent expressly made as of an earlier date, in which case as of such date). If Fortress does not notify the Buyer Indemnified
Party within thirty (30) days following its receipt of an Indemnification Notice that Fortress disputes its liability to the Buyer
Indemnified Party hereunder, such claim specified by the Buyer Indemnified Party in such Indemnification Notice shall be conclusively
deemed a liability of Fortress hereunder and Fortress shall pay the amount of such liability to the Buyer Indemnified Party on
demand. If Fortress agrees that it has an indemnification obligation but asserts that it is obligated to pay a lesser amount than
that claimed by the Buyer Indemnified Party, Fortress shall pay such lesser amount promptly to the Buyer Indemnified Party, without
prejudice to or waiver of the Buyer Indemnified Party’s claim for the difference. Buyer and Fortress hereby covenant and
agree that, to the extent there is a disagreement with respect to a claim for indemnification under this Section 2, they
shall negotiate in good faith to arrive at a resolution of such disagreement. Fortress shall pay to the Buyer Indemnified Parties
any amount of Losses stated in an Indemnity Determination (as defined below) on demand. “Outstanding Indemnification Amount”
means the sum of the amount of Losses stated in all Indemnity Determinations with respect to all indemnification claims by all
Buyer Indemnified Parties pursuant to this Agreement to the extent not actually paid by Fortress to the applicable Buyer Indemnified
Parties as of the Second Stage Closing.

 

    	3

     

    

 

(g)          Subject
to the other provisions of this Section 2, upon a determination of an indemnification claim made by the Buyer Indemnified
Party, whether such determination is by reason of (a) the mutual agreement of Fortress and the Buyer Indemnified Party (or deemed
to be a liability of Fortress pursuant to Section 2(f)), or (b) a judgment or award of a court of competent jurisdiction
(each an “Indemnity Determination”), then the amount of the Losses stated in such Indemnity Determination shall
be paid by Fortress in accordance with the terms of this Section 2 (without prejudice to the Buyer Indemnified Parties’
or Fortress’s right to appeal any such decision, provided that such payment obligation shall not be affected by, delayed
or stayed by any such pending appeal), it being agreed that Fortress’ obligation to pay any Post-Closing Indemnification
Amount or Adjusted Pre-Closing Indemnification Amount shall be limited to the Fortress Portion multiplied by such Post-Closing
Indemnification Amount or Adjusted Pre-Closing Indemnification Amount, as applicable.

 

(h)          For
purposes of this Agreement, “Fundamental Representations” means (x) the representations and warranties of the
Company contained in Section 5.1, Section 5.3, Section 5.4(c), Section 5.5(a), Section 5.5(b), Section 5.5(c), Section 5.8, Section
5.9, Section 5.11, Section 5.14, Section 5.16, Section 5.17 and Section 5.20 of the SPMA and (y) the representations and warranties
of the Company contained in any Ancillary Agreement that are substantially similar to the representations and warranties referred
to in the foregoing clause (x) of this Section 2(h).

 

(i)           In
case of any Proceeding with respect to this Agreement and the rights and obligations arising hereunder, or for recognition
and enforcement of any judgment in respect of this Agreement and the rights and obligations arising hereunder, Fortress
shall use its reasonable best efforts to expedite the resolution of such Proceeding, and acknowledges and agrees that time is of
the essence to the Buyer Indemnified Parties in terms of such resolution.

 

(j)           With
respect to any indemnification claim by a Buyer Indemnified Party hereunder that is not subject to an Indemnity Determination prior
to the Second Stage Closing, if, after the Second Stage Closing, a court of competent jurisdiction dismisses such indemnification
claim on the grounds that it was a frivolous claim, and such dismissal becomes final and not subject to any further appeals or
the time for giving notice to take such appeals has lapsed and no such notice was filed, then Buyer shall reimburse Fortress for
its reasonable and documented legal fees and expenses incurred in connection with the defense of such indemnification claim.

 

    	4

     

    

 

		3.	Representations and Warranties.

 

Fortress represents and warrants to Buyer
as follows:

 

(a)          (i)
It is a corporation duly organized, validly existing and in good standing under the laws of Delaware, (ii) it is duly licensed
and qualified to conduct its business in each jurisdiction where the nature of the properties owned, leased or operated by it and
the business transacted by it requires such licensing or qualification, except where any such failures to be so qualified or licensed
have not had, or are not reasonably likely to have, a material adverse effect on the ability of Fortress to perform its obligations
under or to consummate the transactions contemplated by this Agreement, and (iii) it holds all necessary corporate power and authority
to own, license and operate its assets and properties, to conduct its business, to enter into this Agreement, to perform its obligations
hereunder and to consummate the transactions contemplated hereby.

 

(b)          The
execution and delivery of this Agreement by Fortress and the performance by Fortress of its obligations hereunder have been duly
authorized by all requisite action on the part of Fortress, and no other actions or proceedings on the part of Fortress are necessary
to authorize the execution and delivery of this Agreement.

 

(c)          This
Agreement has been duly executed and delivered by Fortress and constitutes the valid and binding agreement of Fortress, enforceable
against Fortress in accordance with its terms.

 

(d)          The
execution or delivery by Fortress of this Agreement or the performance by Fortress of its obligations under this Agreement will
not (i) result in any breach of any provision of Fortress’ certificate of incorporation or bylaws, as amended, (ii) result
in any breach of, require (with or without notice or lapse of time or both) any payment, consent or notice or constitute a default
(or give rise to any right of purchase, termination, amendment, acceleration or cancellation) under any Contract or order or judgment
to which Fortress is a party or by which it or its assets are bound, (iii) result in the creation of an Encumbrance, or (iv) violate
any applicable Legal Requirement, other than, in the case of clauses (ii) through (iv), such breaches, defaults or violations that
have not had, or are not reasonably likely to have, a material adverse effect on the ability of Fortress to perform its obligations
under or to consummate the transactions contemplated by this Agreement.

 

		4.	Miscellaneous.

 

(a)          Entire
Agreement. This Agreement, together with all other documents referred to herein, constitutes the entire agreement between the
parties hereto with respect to the subject matter of this Agreement and supersedes any and all prior agreements, negotiations,
correspondence, undertakings, understandings and communications of the parties hereto with respect to the subject matter of this
Agreement. Nothing contained in this Agreement shall be deemed or construed as creating a joint venture or partnership between
any of the parties hereto.

 

    	5

     

    

 

(b)          Transaction
Costs. Except as otherwise provided herein, the parties to this Agreement will pay their own costs and expenses (including
legal, accounting and other fees) relating to this Agreement.

 

(c)          Modifications.
Any amendment or modification to this Agreement, including this undertaking itself, shall only be valid if effected by an instrument
or instruments in writing and shall be effective against each of the parties hereto that has signed such instrument or instruments.
The parties agree that they jointly negotiated and prepared this Agreement and that this Agreement will not be construed against
any party on the grounds that such party prepared or drafted the same.

 

(d)          Notices.
Notices will be deemed to have been received (a) upon receipt of a registered letter, (b) three Business Days following proper
deposit with an internationally recognized express overnight delivery service, or (c) in the case of transmission by email, as
of the date so transmitted (or if so transmitted after normal business hours at the place of the recipient, on the Business Day
following such transmission):

 

If to Fortress:

 

Fortress Biotech, Inc.

2 Gansevoort Street,
9th Floor

New York, NY 10014

Attn: Dr. Lindsay Rosenwald,
M.D.

Email: lrosenwald@fortressbiotech.com

 

With a copy (which shall
not constitute notice) to:

 

Fortress Biotech, Inc.

2 Gansevoort Street,
9th Floor

New York, NY 10014

Attn: Samuel W. Berry,
Esq.

Email: sberry@fortressbiotech.com

 

If to Buyer:

 

InvaGen Pharmaceuticals
Inc.

Site B, 7 Oser Ave.

Hauppauge, NY 11788

c/o

A.S. Kumar, Esq.

Global General Counsel

Cipla Ltd.

Cipla House, Peninsula
Business Park,

Ganapatrao Kadam Marg,
Lower Parel West,

Mumbai, Maharashtra
400013, India

Email: as.kumar@cipla.com and cosecretary@cipla.com

 

    	6

     

    

 

With a copy (which shall
not constitute notice) to:

 

InvaGen Pharmaceuticals
Inc.

Site B, 7 Oser
Ave.

Hauppauge,
NY 11788

c/o

Nishant Saxena

Global Chief
Strategy Officer

Cipla Ltd.

Cipla House,
Peninsula Business Park,

Ganapatrao
Kadam Marg, Lower Parel West,

Mumbai, Maharashtra
400013, India

Email: nishant.saxena@cipla.com

 

With a copy (which shall
not constitute notice) to:

 

Hughes Hubbard &
Reed LLP

One Battery Park Plaza

New York, NY 10004-1482

Attn: Kenneth A. Lefkowitz

Email: ken.lefkowitz@hugheshubbard.com

 

or to such other address
as may be hereafter communicated in writing by the parties in a notice given in accordance with this Section 4(d), which
address shall then apply to the respective notice provisions of the SPMA and all other Ancillary Agreements.

 

(e)          Public
Announcements. Except as required by Legal Requirements or by the requirements of any stock exchange on which the securities
of a party hereto or any of its Affiliates are listed, no party to this Agreement will make, or cause to be made, any press release
or public announcement in respect of this Agreement or the transactions contemplated hereby or otherwise communicate with any news
media with respect to the foregoing without prior notification to the other parties, and the parties to this Agreement will consult
with each other and cooperate as to the form, timing and contents of any such press release, public announcement or disclosure.

 

(f)           Severability.
Each provision of this Agreement will be interpreted in such manner as to be effective and valid under applicable Legal Requirements,
but if any provision of this Agreement is found to be unenforceable or invalid under applicable Legal Requirements, such provision
will be ineffective only to the extent of such unenforceability or invalidity, and the parties will negotiate in good faith to
modify this Agreement so that the unenforceable or invalid provision is replaced by such valid and enforceable provision which
the parties consider, in good faith, to match as closely as possible the invalid or unenforceable provision and to achieve the
same or a similar economic effect and to give effect to the parties’ original intent. The remaining provisions of this Agreement
will continue to be binding and in full force and effect.

 

    	7

     

    

 

(g)          Assignment.
No party hereto may assign, in whole or in part, or delegate all or any part of its rights, interests or obligations under this
Agreement without the prior written consent of the other party. Any assignment or delegation made without such consent will be
void. Notwithstanding the foregoing, Buyer shall be entitled to (a) assign its rights under this Agreement to any one of its Affiliates,
and (b) assign any or all of its rights and obligations under this Agreement (in whole or in part) as collateral security in a
financing transaction.

 

(h)          Confidentiality
Agreement. The terms of the Confidentiality Agreement are hereby incorporated herein by reference and will continue in full
force and effect until expiration or termination in accordance with the terms therein.

 

(i)           Governing
Law. This Agreement and any claims or causes of action pursuant to it will be governed by and construed in accordance with
the laws of the State of Delaware, without regard for its principles of conflict of laws.

 

(j)           Specific
Performance. Each party acknowledges and agrees that the other party would be irreparably damaged if the provisions of this
Agreement are not performed in accordance with their terms and that any breach of this Agreement and the non-consummation of the
transactions contemplated hereby by either party could not be adequately compensated in all cases by monetary damages alone. Accordingly,
in addition to any remedy to which such other party may be entitled under Section 4(k), provisional measures and injunctive
relief necessary to protect the possibility of each party to seek specific performance from the other from the tribunal referred
to in Section 4(k) can be sought from any court of competent jurisdiction. Each of the parties hereto (i) agrees that it
shall not oppose the granting of any such relief and (ii) hereby irrevocably waives any requirement for the security or posting
of any bond in connection with any such relief (it is understood that clause (i) of this sentence is not intended to, and shall
not, preclude any party hereto from litigating on the merits the substantive claim to which such remedy relates).

 

(k)          Submission
to Jurisdiction. Each of the parties hereto irrevocably agrees that any Proceeding with respect to this Agreement and
the rights and obligations arising hereunder, or for recognition and enforcement of any judgment in respect of this Agreement and
the rights and obligations arising hereunder brought by any other party hereto or its successors or assigns, shall be brought and
determined exclusively in the Court of Chancery of the State of Delaware, or in the event (but only in the event) that such court
does not have subject matter jurisdiction over such action or proceeding, in the federal courts sitting in the State of Delaware.
Each of the parties hereto agrees that mailing of process or other papers in connection with any such action or proceeding in the
manner provided in Section 4(d), or in such other manner as may be permitted by applicable Legal Requirements, will
be valid and sufficient service thereof. Each of the parties hereto hereby irrevocably submits with regard to any such action or
proceeding for itself and in respect of its property, generally and unconditionally, to the personal jurisdiction of the aforesaid
courts and agrees that it will not bring any action relating to this Agreement or any of the transactions contemplated
by this Agreement in any court or tribunal other than the aforesaid courts. Each of the parties hereto hereby irrevocably
waives, and agrees not to assert, by way of motion, as a defense, counterclaim, or otherwise, in any action or proceeding with
respect to this Agreement and the rights and obligations arising hereunder, or for recognition and enforcement of any
judgment in respect of this Agreement and the rights and obligations arising hereunder: (a) any claim that it is not
personally subject to the jurisdiction of the above named courts for any reason other than the failure to serve process in accordance
with this Section 4(k); (b) any claim that it or its property is exempt or immune from jurisdiction of any such court
or from any legal process commenced in such courts (whether through service of notice, attachment prior to judgment, attachment
in aid of execution of judgment, execution of judgment or otherwise); and (c) to the fullest extent permitted by the applicable
Legal Requirements, any claim that (i) the suit, action or proceeding in such court is brought in an inconvenient forum, (ii) the
venue of such suit, action or proceeding is improper, or (iii) this Agreement, or the subject matter hereof, may not be enforced
in or by such courts.

 

    	8

     

    

 

(l)           Waiver
of Jury Trial. EACH PARTY ACKNOWLEDGES AND AGREES THAT ANY CONTROVERSY WHICH MAY ARISE UNDER THIS AGREEMENT IS LIKELY
TO INVOLVE COMPLICATED AND DIFFICULT ISSUES AND, THEREFORE, EACH SUCH PARTY IRREVOCABLY AND UNCONDITIONALLY WAIVES ANY RIGHT IT
MAY HAVE TO A TRIAL BY JURY IN RESPECT OF ANY LEGAL ACTION ARISING OUT OF OR RELATING TO THIS AGREEMENT or
the transactions contemplated hereby. EACH PARTY TO THIS AGREEMENT CERTIFIES AND ACKNOWLEDGES THAT: (A) NO REPRESENTATIVE
OF ANY OTHER PARTY HAS REPRESENTED, EXPRESSLY OR OTHERWISE, THAT SUCH OTHER PARTY WOULD NOT SEEK TO ENFORCE THE FOREGOING WAIVER
IN THE EVENT OF A LEGAL ACTION; (B) SUCH PARTY HAS CONSIDERED THE IMPLICATIONS OF THIS WAIVER; (C) SUCH PARTY MAKES THIS WAIVER
VOLUNTARILY; AND (D) SUCH PARTY HAS BEEN INDUCED TO ENTER INTO THIS AGREEMENT BY, AMONG OTHER THINGS, THE MUTUAL WAIVERS AND
CERTIFICATIONS IN THIS SECTION 4(l).

 

(m)          Waiver.
Any term or condition of this Agreement may be waived at any time by the party that is entitled to the benefit thereof, but no
such waiver shall be effective unless set forth in a written instrument duly executed by or on behalf of the party waiving such
term or condition, and no waiver by any party of any default, misrepresentation, or breach of warranty or covenant hereunder, shall
be deemed to extend to any prior or subsequent default, misrepresentation, or breach of warranty, covenant or agreement hereunder
or affect in any way any rights arising by virtue of any such prior or subsequent occurrence. No failure or delay of any party
in exercising any right or remedy hereunder shall operate as a waiver thereof, and no waiver by any party of any term or condition
of this Agreement, in any one or more instances, shall be deemed to be or construed as a waiver of the same or any other term or
condition of this Agreement on any future occasion.

 

(n)          Counterparts;
Facsimile Signature. This Agreement may be executed in one (1) or more counterparts, by original or facsimile (or other such
electronically transmitted) signature, each of which will be deemed an original, but all of which will constitute one and the same
instrument. A party executing this Agreement by facsimile (or other such electronically transmitted) signature shall, upon request
from another party, promptly deliver to the requesting party an original counterpart of such signature.

 

    	9

     

    

 

(o)          Rights
Cumulative. All rights and remedies of each of the parties under this Agreement will be cumulative, and the exercise of one
or more rights or remedies will not preclude the exercise of any other right or remedy available under this Agreement or applicable
Legal Requirements.

 

(p)          Interpretation.
(a) The words “hereof”, “herein”, and “hereunder” and words of similar import, when used in
this Agreement, shall refer to this Agreement as a whole and not to any particular provision of this Agreement; (b) the words
“date hereof,” when used in this Agreement, shall refer to the date set forth in the Preamble; (c) the terms defined
in the singular have a comparable meaning when used in the plural, and vice versa; (d) the terms defined in the present tense
have a comparable meaning when used in the past tense, and vice versa; (e) any references herein to a specific Section or
Article shall refer, respectively, to Sections or Articles of this Agreement; (f) wherever the word “include”,
“includes”, or “including” is used in this Agreement, it shall be deemed to be followed by the words “without
limitation”; (g) references herein to any gender includes each other gender; (h) the word “or” shall
not be exclusive; (i) the headings herein are for convenience of reference only, do not constitute part of this Agreement
and shall not be deemed to limit or otherwise affect any of the provisions hereof; (j) any references herein to any Governmental
Authority shall be deemed to also be a reference to any successor Governmental Authority thereto; and (k) the parties hereto have
participated jointly in the negotiation and drafting of this Agreement and, in the event that an ambiguity or question of intent
or interpretation arises, this Agreement shall be construed as jointly drafted by the parties hereto and no presumption or burden
of proof shall arise favoring or disfavoring any party by virtue of the authorship of any provision of this Agreement.

 

(q)          Effectiveness.
This Agreement shall become effective as of the Effective Date. If the SPMA is terminated in accordance with its terms prior to
the First Stage Closing, this Agreement shall automatically terminate. This Agreement shall automatically terminate upon the Second
Stage Closing. Notwithstanding the preceding two sentences, this Section 4 shall survive any termination of this Agreement and
any breach hereof prior to such termination shall survive such termination. Notwithstanding anything herein to the contrary, the
obligations under this Agreement shall not terminate with respect to any claim, whether or not fixed as to liability or liquidated
as to amount, with respect to which Fortress has been given an Indemnification Notice.

 

    	10

     

    

 

IN WITNESS WHEREOF,
the parties have caused this Agreement to be duly executed as of the date first written above.

 

	 	Fortress Biotech, Inc.
	 	 

	 	By:	/s/  Lindsay A. Rosenwald
	 	Name:      	 Lindsay A. Rosenwald
	 	Title:	President and CEO

 

	 	InvaGen Pharmaceuticals Inc.
	 	 

	 	By:	/s/ Deepak Agarwal
	 	Name:      	Deepak Agarwal
	 	Title:	CFO

 

[Signature Page
to Indemnification Agreement]

 

    	11

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00289-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00289-of-00352.parquet"}]]